Macrogenics (MGNX) – FDA
-
Macrogenics (MGNX) Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
-
Macrogenics (MGNX) Achieves $15M Milestone Related to Gilead’s (GILD) Nomination of a Bispecific Research Program
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to MGNX Stock Lookup